SARS CoV-2 infections in healthcare workers with a pre-existing T-cell response: a prospective cohort study

Clin Microbiol Infect. 2021 Jun;27(6):916.e1-916.e4. doi: 10.1016/j.cmi.2021.02.020. Epub 2021 Mar 2.

Abstract

Objective: T-cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are observed in unexposed individuals. We evaluated the impact of this pre-existing cellular response on incident SARS-CoV-2 infections.

Methods: This was a follow-up study of 38 seronegative healthcare workers (HCWs) with previous evaluation of CD8+ and CD4+ T-cell responses after stimulation with SARS-CoV-2 structural proteins. Infection was considered in the presence of a positive RT-PCR test and/or confirmed seroconversion.

Results: Twenty of the 38 HCWs included (53%) had a previous specific CD8+ T-cell response to peptides encompassing the spike protein (S) in 13 (34%), the membrane (M) in 17 (45%), or/and the nucleocapsid (N) in three (8%). During a follow-up of 189 days (interquartile range (IQR) 172-195), 11 HCWs (29%) had an RT-PCR-positive test (n = 9) or seroconverted (n = 2). Median duration of symptoms was 2 days (IQR 0-7), and time to negative RT-PCR was 9 days (IQR 4-10). Notably, six incident infections (55%) occurred in HCWs with a pre-existing T-cell response (30% of those with a cellular response), who showed a significantly lower duration of symptoms (three were asymptomatic). Three of the six HCWs having a previous T-cell response continued to test seronegative. All the infected patients developed a robust T-cell response to different structural SARS-CoV-2 proteins, especially to protein S (91%).

Conclusion: A pre-existing T-cell response does not seem to reduce incident SARS-CoV-2 infections, but it may contribute to asymptomatic or mild disease, rapid viral clearance and differences in seroconversion.

Keywords: COVID-19; Cross-reactivity; Healthcare workers; Immune response; SARS-CoV-2; T-cell response.

MeSH terms

  • Adult
  • Antibodies, Viral
  • COVID-19 / immunology*
  • COVID-19 Nucleic Acid Testing
  • Female
  • Follow-Up Studies
  • Health Personnel
  • Humans
  • Immunity
  • Male
  • Middle Aged
  • Prospective Studies
  • Seroconversion
  • T-Lymphocytes / immunology*
  • Viral Structural Proteins / immunology*
  • Young Adult

Substances

  • Antibodies, Viral
  • Viral Structural Proteins